NYSE
$1.24
(1.18%)
Subscribe to get
AI Score
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and...
Incyte Corp (NASDAQ:INCY) experienced a daily gain of 0.89% and a 3-month loss of -6.29%. The...
Incyte Corp (INCY) reports a 24% revenue increase, driven by Jakafi and Opzelura, while navigating...
Momentum investing is all about the idea of following a stock's recent trend, which can be in either...
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Ligand...
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat...
Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The...
A month has gone by since the last earnings report for Incyte (INCY). Shares have added about 2.1%...
Incyte INCY suffered a setback in its ongoing mid-stage study on MRGPRX2 (INCB000262) in chronic...
Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross...